Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 13.84B 749M 665M 617M 561M 1.06B 71.05B 1.08B 7.41B 2.91B 37.08B 2.81B 2.75B 118B P/E 2026 *
7.29x
P/E 2027 * 7.18x
Enterprise Value 18.03B 975M 867M 804M 731M 1.38B 92.57B 1.4B 9.66B 3.79B 48.3B 3.66B 3.58B 154B EV / Sales 2026 *
1.01x
EV / Sales 2027 * 0.93x
Free-Float
68.95%
Yield 2026 *
5.64%
Yield 2027 * 7.55%
1 day+2.98%
1 week+8.82%
Current month+12.89%
1 month+12.89%
3 months-3.86%
6 months-24.48%
Current year-20.68%
1 week 13
Extreme 13
14.3
1 month 12.22
Extreme 12.22
14.3
Current year 12.22
Extreme 12.22
19.48
1 year 12.22
Extreme 12.22
19.48
3 years 12.22
Extreme 12.22
29.18
5 years 12.22
Extreme 12.22
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 12/04/2023
Director of Finance/CFO - 01/12/2015
Investor Relations Contact - 01/10/2019
Director TitleAgeSince
Chairman - 30/10/1996
Director/Board Member - 06/07/2010
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.98%+8.82%-18.26%+6.05% 749M
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average +0.14%+4.09%+29.14%+55.73% 394.16B
Weighted average by Cap. +0.13%+3.83%+39.33%+71.81%

Financials

2026 *2027 *
Net sales 17.81B 963M 856M 794M 722M 1.36B 91.43B 1.38B 9.54B 3.74B 47.71B 3.62B 3.54B 152B 18.74B 1.01B 901M 835M 760M 1.43B 96.23B 1.46B 10.04B 3.94B 50.22B 3.81B 3.72B 160B
Net income 1.95B 106M 93.82M 86.96M 79.12M 149M 10.02B 152M 1.05B 410M 5.23B 396M 388M 16.66B 2.06B 111M 98.98M 91.74M 83.47M 158M 10.57B 160M 1.1B 432M 5.51B 418M 409M 17.58B
Net Debt 4.19B 227M 202M 187M 170M 321M 21.52B 326M 2.25B 880M 11.23B 851M 833M 35.8B 3.67B 198M 176M 163M 149M 281M 18.82B 285M 1.96B 770M 9.82B 744M 728M 31.31B
Projected Income Statement - Annual - Genomma Lab Internacional, S.A.B. de C.V.
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,658
Date Price Change Volume
16/10/26 MX$14.19 +2.98% 4,587,020
15/10/26 MX$13.78 0.00% 3,550,065
14/10/26 MX$13.78 +3.53% 6,402,847
13/10/26 MX$13.31 +1.68% 5,635,182
12/10/26 MX$13.09 +0.38% 3,424,687
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genomma Lab Internacional, S.A.B. de C.V.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.19MXN
Average target price
21.33MXN
Spread / Average Target
+50.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genomma Lab Internacional, S.A.B. de C.V.
  1. Stock Market
  2. Stocks
  3. LAB B Stock